What pharmacologic options can be used to treat progressive supranuclear palsy in an older adult who does not benefit from levodopa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pharmacologic Treatment Options for Progressive Supranuclear Palsy Beyond Levodopa

For older adults with progressive supranuclear palsy (PSP) who do not benefit from levodopa, the most evidence-supported pharmacologic options are tricyclic antidepressants (particularly amitriptyline) and botulinum toxin for specific symptoms, though all pharmacologic interventions show limited efficacy and should be targeted to specific symptom domains rather than global disease modification. 1, 2

Evidence-Based Symptomatic Treatment Options

Tricyclic Antidepressants

  • Amitriptyline demonstrated benefit in 32% of PSP patients in a retrospective study of 87 patients, with one of the best risk/benefit ratios among all medications tested. 2
  • Imipramine showed benefit in 28% of patients and also had a favorable risk/benefit profile. 2
  • These agents may help with behavioral symptoms and depression, though they are often poorly tolerated due to adverse effects in elderly patients. 1

Botulinum Toxin Injections

  • Intramuscular botulinum toxin is effective for reducing dystonia, including blepharospasm, which is a common disabling feature in PSP. 1
  • Intrasalivary gland botulinum toxin injections are useful for managing problematic sialorrhea. 1

Medications for Specific Movement Disorders

For Dystonia:

  • Baclofen can reduce dystonic symptoms. 1
  • Benzodiazepines may also help manage dystonia. 1

For Myoclonus:

  • Levetiracetam is recommended as first-line treatment. 1
  • Benzodiazepines serve as an alternative option. 1

Other Dopaminergic Agents

  • Amantadine showed one of the best risk/benefit ratios in the retrospective study, though specific response rates were not detailed. 2
  • Selegiline also demonstrated a favorable risk/benefit profile. 2
  • Monotherapy with these agents tended to show more benefit and fewer adverse effects than polypharmacy. 2

Important Caveats and Pitfalls

What NOT to Use

Avoid acetylcholinesterase inhibitors and memantine:

  • These agents, licensed for Alzheimer's disease, have been used off-label in PSP with the aim of improving cognition, but there is limited evidence of effectiveness and the risk of adverse effects may outweigh benefits. 1

Avoid typical and most atypical antipsychotics:

  • Antipsychotics are not recommended in elderly patients or those with dementia-associated conditions. 1
  • Most antipsychotics will worsen Parkinsonism, which is already a core feature of PSP. 1
  • Phenothiazines, butyrophenones, and risperidone may reduce the therapeutic effects of any residual dopaminergic therapy. 3

Avoid dopamine-depleting agents:

  • Reserpine and tetrabenazine are not recommended as they deplete monoamine stores. 3

Levodopa-Related Considerations

  • In autopsy-confirmed PSP cases, only 7 of 12 patients showed any positive response to dopaminergic drugs, with no marked or persistent beneficial effects. 4
  • Disabling adverse effects from levodopa in PSP patients included orthostatic hypotension (50% of patients), hallucinations and delusions (25%), gastrointestinal complaints (25%), and dizziness. 4
  • Interestingly, only 1 patient developed dyskinesia, which is much lower than in Parkinson's disease. 4
  • The relative predominance of serotonin over dopamine in PSP basal ganglia may contribute to poor levodopa responsiveness, suggesting that combination therapy with a serotonin receptor blocker might theoretically improve response, though this remains unproven. 5

Drug Interactions to Monitor

  • Iron salts or multivitamins containing iron should be coadministered with caution if any dopaminergic therapy is continued, as they can form chelates with levodopa and carbidopa, reducing bioavailability. 3
  • Metoclopramide may adversely affect disease control through its dopamine receptor antagonistic properties despite increasing levodopa bioavailability. 3

Realistic Expectations

  • There are currently no disease-modifying treatments for PSP, and no approved pharmacological treatments that are effective in controlling global symptoms. 1
  • Most pharmacological treatment options are based on experience in other disorders, case series, or expert opinion rather than randomized controlled trials. 1
  • Antiparkinsonian medications and other neurotransmitter replacement therapies are largely ineffective and cause frequent adverse effects in PSP. 4
  • Management should focus on optimizing quality of life, relieving specific symptoms, and assisting with activities of daily living through a multidisciplinary team approach including physiotherapy, occupational therapy, speech and language therapy, dieticians, ophthalmology, psychology, and palliative care. 1

References

Related Questions

What medications, other than levodopa, can be used to treat progressive supranuclear palsy in an adult?
What is the maximum dose of levodopa (L-dopa) that can be used in a patient with Progressive Supranuclear Palsy (PSP)?
What is the management approach for patients with Progressive Supranuclear Palsy (PSP) and other Parkinson-plus syndromes?
What is the management of corticobasal degeneration?
What medication is recommended to treat an overactive (hyper‑reflexive) bladder in a patient with progressive supranuclear palsy?
What are the causes of rapidly progressive glomerulonephritis?
Why should a patient who had two provoked pulmonary emboli—one after COVID‑19 infection and another after spine surgery—receive indefinite anticoagulation?
What deep tendon reflex findings are expected on physical examination in a patient with Pott disease (tuberculous spondylitis)?
In a patient with a recent surgery‑provoked pulmonary embolism who is completing a three‑month course of therapeutic anticoagulation, does the presence of familial hypercholesterolemia require indefinite anticoagulation?
In a woman with known pulmonary hypertension, what postpartum complications should be anticipated and what should be monitored after delivery?
What are the long‑term side effects of testosterone replacement therapy when dosed to maintain serum testosterone within the normal physiological range?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question